Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses.
Noureddin N, Ajmera V, Bergstrom J, Bettencourt R, Huang DQ, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Loomba R. Noureddin N, et al. Among authors: tamaki n. Aliment Pharmacol Ther. 2023 Nov;58(9):856-865. doi: 10.1111/apt.17707. Epub 2023 Sep 11. Aliment Pharmacol Ther. 2023. PMID: 37694993
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Apr;40(4):251-60. doi: 10.1111/j.1872-034X.2009.00607.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070391
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Sep;40(9):870-7. doi: 10.1111/j.1872-034X.2010.00692.x. Hepatol Res. 2010. PMID: 20887591
Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy.
Hosokawa T, Kurosaki M, Tsuchiya K, Matsuda S, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Nakata T, Nishimura T, Suzuki S, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Hosokawa T, et al. Among authors: tamaki n. World J Gastroenterol. 2013 Jan 14;19(2):249-57. doi: 10.3748/wjg.v19.i2.249. World J Gastroenterol. 2013. PMID: 23345948 Free PMC article.
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Asahina Y, et al. Among authors: tamaki n. Hepatology. 2013 Oct;58(4):1253-62. doi: 10.1002/hep.26442. Epub 2013 Aug 19. Hepatology. 2013. PMID: 23564522
1,566 results